Astrana Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASTH research report →
Range $53 – $65
Price Chart
About the company
Astrana Health, Inc. , which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985.
- CEO
- Brandon K. Sim
- IPO
- 2009
- Employees
- 3,000
- HQ
- Alhambra, CA, US
Get TickerSpark's AI analysis on ASTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43B
- P/E
- 29.62
- Fwd P/E
- 23.28
- PEG
- 0.07
- P/S
- 0.41
- P/B
- 1.84
- EV/EBITDA
- 10.11
- Div Yield
- 0.00%
- Gross Margin
- 10.14%
- Op Margin
- 3.10%
- Net Margin
- 1.36%
- ROE
- 6.51%
- ROIC
- 5.02%
Latest fiscal year · YoY change
- Revenue
- $3.18B+56.4%
- Gross Profit
- $295.78M+9.0%
- Op Income
- $78.53M
- Net Income
- $22.49M-47.9%
- EPS
- $0.46-49.5%
- OCF Growth
- +119.5%
- FCF Growth
- +136.6%
- 52W High
- $51.60
- 52W Low
- $18.08
- 50D MA
- $35.82
- 200D MA
- $34.48
- Beta
- 0.91
- RSI (14)
- 29
- Avg Volume
- 376.46K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Astrana reported record third-quarter revenue and EBITDA, with strong free cash flow, lower leverage, and management still confident in mid-teens EBITDA growth into 2027 despite Medicaid headwinds.· November 5, 2026
- Revenue hit a record $1.02 billion, up 7% year over year; adjusted EBITDA was a record $77.2 million, up 13% year over year, and adjusted diluted EPS was $0.71.
- Free cash flow was approximately $105 million through the first 9 months; the company repaid $116 million of debt year to date and ended with net leverage of 2.2x.
- Management said Texas full-risk cohorts are outperforming plan, Medicare Advantage remains stable into 2027, and capitation revenue should be about 82% full risk by year-end.
- Medicaid remains the biggest pressure point: membership attrition is expected at the middle to high end of the 10% to 15% range, and trend is running above initial assumptions.
- Care Enablement is emerging as a growth lever, with over $300 million of segment revenue and new client wins in Connecticut and California.
Third-quarter revenue was $1.02 billion, up 7% year over year. Adjusted EBITDA was $77.2 million, up 13% year over year and at the high end of guidance, and adjusted diluted EPS was $0.71. Net income attributable to Astrana was $13 million. G&A was 6.6% of revenue in the quarter and 6.2% year to date. Free cash flow was approximately $105 million through the first 9 months, and year-to-date debt reduction was approximately $116 million. The company ended the quarter with $396 million in cash and $581 million of net debt, with trailing 12-month gross leverage at 3.7x and net leverage at 2.2x. For full year 2026, Astrana narrowed guidance to revenue of $3.9 billion to $4 billion, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million. For the fourth quarter, it expects revenue of $939 million to $1.04 billion and adjusted EBITDA of $48.5 million to $61.5 million. Management said overall medical cost trend year to date is slightly better than the approximately 5.2% assumption embedded in full-year guidance.
Brandon Sim framed the quarter as evidence that Astrana’s platform is compounding, with intelligence, alignment, and delivery creating operating leverage across risk-bearing care, technology, and provider networks. He emphasized that growth is coming from maturing cohorts, better medical cost performance, and expansion into new markets and products, while still balancing reinvestment with profitability. His tone was confident and long-term focused, repeatedly describing the business as early in its potential and capable of at least mid-teens annual adjusted EBITDA growth over the medium term.
Chandan Basho focused on execution, noting that adjusted EBITDA came in at the high end of guidance, free cash flow remained strong, and leverage continued to decline. He highlighted $105 million of free cash flow through the first 9 months, $116 million of debt reduction, $396 million of cash, and net leverage of 2.2x, and said the company is on track to approach 2x net leverage by year-end. He also explained the evolving ACO revenue presentation, including the new supplemental measure of gross equivalent consolidated premiums, which he said would be about $4.45 billion for 2026 versus reported revenue guidance of $3.9 billion to $4 billion.
Analysts pressed on Care Enablement, Medicare Advantage rates, Medicaid acuity and attrition, the cyber incident, ACO accounting, and the new premiums-at-risk metric. Management said Care Enablement is already a more than $300 million business, is attracting organic demand without a dedicated sales force, and could become more meaningful over time; on MA, they said the 2027 rate environment looks stable and contracts are economically sound. On Medicaid, they acknowledged rising acuity and planned conservatively for a 10% to 15% membership decline in 2027, while saying some policy changes could soften the impact but are too early to include in guidance. On the cyber incident, they said the matter remains under investigation and declined to quantify impact beyond noting ongoing remediation and law enforcement involvement.
The call showed a business with record revenue, record adjusted EBITDA, strong free cash flow, and clear deleveraging progress. Management also pointed to outperformance in Texas, stable MA margins, expanding Care Enablement demand, and continued synergies from Prospect, all of which support the case for durable mid-teens EBITDA growth.
The main risks discussed were Medicaid headwinds, including weaker trend, possible adverse selection, and expected 10% to 15% membership declines in 2027, plus uncertainty around policy changes and ACO program transitions. Management also noted a cyber incident under investigation and said fourth-quarter profitability will be seasonally the weakest quarter, with earnings affected by Medicaid attrition, onboarding costs, and non-repeating items from the third quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 76.5%
- Shares Outstanding
- 49.60M
- Float Shares
- 37.95M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 201 ETFs
Biggest fund positions in ASTH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Vong John | other | 642 |
| Oct 10, 26 | Vong John | other | 556 |
| Oct 6, 26 | Sim Brandon | other | 9,889 |
| Oct 6, 26 | Lam Thomas S. | other | 2,624 |
| Oct 2, 26 | Basho Chandan | other | 2,092 |
| Sep 15, 26 | Vong John | other | 96 |
| Sep 5, 26 | Sim Brandon | other | 7,163 |
| Sep 5, 26 | Basho Chandan | other | 1,790 |
| Aug 31, 26 | Kitayama Mitchell W | sell | 8,500 |
| Aug 14, 26 | Schmidt David | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASTH coverage
Recent articles, reports, and earnings notes.
No research on ASTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASTH report →Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement
prnewswire.com · Nov 10
Astrana Health, Inc. (ASTH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Astrana Health Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Astrana Health, Inc. (ASTH) Q3 Earnings Lag Estimates
zacks.com · Nov 5
Astrana Health, Inc. Reports Third Quarter 2026 Results
prnewswire.com · Nov 5
Diamond Hill Small Cap Fund Q3 2026 Portfolio Activity
seekingalpha.com · Oct 28
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH
prnewswire.com · Oct 22
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH
globenewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.